Kinase double shot

Based on the binding mechanisms of Gleevec imatinib and Nexavar sorafenib,University of California, San Diego researchers have created a dual kinase inhibitor that selectively hits one of each drug's many targets: RAF and PDGFRB.¹ Kinagen Inc. has in-licensed the IP and hopes to move a similar compound into the clinic next year.

In the long-running debate on how selective kinase inhibitors should be, the UCSD group's work falls on the narrow end of the spectrum...